J
Janet L. Nichol
Researcher at Amgen
Publications - 60
Citations - 5570
Janet L. Nichol is an academic researcher from Amgen. The author has contributed to research in topics: Platelet & Megakaryocyte. The author has an hindex of 32, co-authored 60 publications receiving 5334 citations. Previous affiliations of Janet L. Nichol include University of Amsterdam & Puget Sound Blood Center.
Papers
More filters
Journal ArticleDOI
Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial
David J. Kuter,James B. Bussel,Roger M. Lyons,Vinod Pullarkat,Terry Gernsheimer,Francis M. Senecal,Louis M. Aledort,James N. George,Craig M. Kessler,Miguel A. Sanz,Howard A. Liebman,Frank T. Slovick,J. Th. M. de Wolf,Emmanuelle Bourgeois,Troy H. Guthrie,Adrian C. Newland,Jeffrey S. Wasser,Solomon I. Hamburg,Carlos Grande,François Lefrère,Alan E. Lichtin,Michael D. Tarantino,Howard R. Terebelo,Jean François Viallard,Francis J. Cuevas,Ronald S. Go,David H. Henry,Robert L. Redner,Lawrence Rice,Martin R. Schipperus,D. Matthew Guo,Janet L. Nichol +31 more
TL;DR: Romiplostim was well tolerated, and increased and maintained platelet counts in splenectomised and non-splenECTomised patients with ITP and treatment safety was good.
Journal ArticleDOI
AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP.
James B. Bussel,David J. Kuter,James N. George,Robert McMillan,Louis M. Aledort,George T. Conklin,Alan E. Lichtin,Roger M. Lyons,Jorge Nieva,Jeffrey S. Wasser,Israel Wiznitzer,Reggie Kelly,Chien Feng Chen,Janet L. Nichol +13 more
TL;DR: AMG 531 caused no major adverse events and increased platelet counts in patients with ITP, and increases in the platelet count were dose-dependent.
Journal ArticleDOI
Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP
TL;DR: It is shown that plasma autoantibody from some adult patients with ITP inhibits in vitro megakaryocyte production, suggesting that a similar effect may occur in vivo.
Journal ArticleDOI
Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP.
TL;DR: In conclusion, romiplostim increased platelet counts in most patients for up to 156 weeks without tachyphylaxis and had an acceptable safety profile.
Journal ArticleDOI
Platelets generated in vitro from proplatelet-displaying human megakaryocytes are functional
TL;DR: This is the first description of an in vitro culture system that sequentially demonstrates megakaryocyte growth, development, and platelet production.